Interferon-γ-stimulated marrow stromal cells:: a new type of nonhematopoietic antigen-presenting cell

被引:228
作者
Stagg, J
Pommey, S
Eliopoulos, N
Galipeau, J
机构
[1] Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[2] Jewish Gen Hosp, Div Hematol Oncol, Montreal, PQ, Canada
[3] McGill Univ, Montreal, PQ, Canada
关键词
D O I
10.1182/blood-2005-07-2793
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several studies have demonstrated that marrow stromal cells (MSCs) can suppress allogeneic T-cell responses. However, the effect of MSCs on syngeneic immune responses has been largely overlooked. We describe here that primary MSCs derived from C57BL/6 mice behave as conditional antigen-presenting cells (APCs) and can induce antigen-specific protective immunity. Interferon gamma (IFN gamma)-treated C57BL/6 MSCs, but not unstimulated MSCs, cocultured with ovalburnin-specific major histocompatibility (MHC) class II-restricted hybridomas in the presence of soluble ovalburnin-induced significant production of interleukin-2 (IL-2) in an antigen dose-dependent manner (P < .005). IFN gamma-treated MSCs could further activate in vitro ovalburnin-specific primary transgenic CD4(+) T cells. C57BL/6 MSCs, however, were unable to induce antigen cross-presentation via the MHC class I pathway. When syngeneic mice were immunized intraperitoneally with ovalbumin-pulsed IFN gamma-treated MSCs, they developed antigen-specific cytotoxic CD8(+) T cells and became fully protected (10 of 10 mice) against ovalbumin-expressing E.G7 tumors. Human MSCs were also studied for antigen-presenting functions. IFN gamma-treated DR1-positive human MSCs, but not unstimulated human MSCs, induced significant production of IL-2 when cocultured with DR1-restricted influenza-specific humanized T-cell hybridomas in the presence of purified influenza matrix protein 1. Taken together, our data strongly suggest that MSCs behave as conditional APCs in syngeneic immune responses.
引用
收藏
页码:2570 / 2577
页数:8
相关论文
共 65 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]   Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo [J].
Al-Khaldi, A ;
Eliopoulos, N ;
Martineau, D ;
Lejeune, L ;
Lachapelle, K ;
Galipeau, J .
GENE THERAPY, 2003, 10 (08) :621-629
[3]   Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo [J].
Bartholomew, A ;
Patil, S ;
Mackay, A ;
Nelson, M ;
Buyaner, D ;
Hardy, W ;
Mosca, J ;
Sturgeon, C ;
Siatskas, M ;
Mahmud, N ;
Ferrer, K ;
Deans, R ;
Moseley, A ;
Hoffman, R ;
Devine, SM .
HUMAN GENE THERAPY, 2001, 12 (12) :1527-1541
[4]   Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness [J].
Beyth, S ;
Borovsky, Z ;
Mevorach, D ;
Liebergall, M ;
Gazit, Z ;
Aslan, H ;
Galun, E ;
Rachmilewitz, J .
BLOOD, 2005, 105 (05) :2214-2219
[5]   Presentation of exogenous protein antigens on major histocompatability complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines [J].
Brossart, P ;
Bevan, MJ .
BLOOD, 1997, 90 (04) :1594-1599
[6]   Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production [J].
Brown, JA ;
Dorfman, DM ;
Ma, FR ;
Sullivan, EL ;
Munoz, O ;
Wood, CR ;
Greenfield, EA ;
Freeman, GJ .
JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1257-1266
[7]   Interferon-γ mediates antigen trafficking to MHC class II-positive late endosomes of enterocytes [J].
Büning, J ;
Schmitz, M ;
Repenning, B ;
Ludwig, D ;
Schmidt, MA ;
Strobel, S ;
Zimmer, KP .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (03) :831-842
[8]   T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing [J].
Canaday, DH ;
Gehring, A ;
Leonard, EG ;
Eilertson, B ;
Schreiber, JR ;
Harding, CV ;
Boom, WH .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 281 (1-2) :129-142
[9]   Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice [J].
Chuah, MKL ;
Van Damme, A ;
Zwinnen, H ;
Goovaerts, I ;
Vanslembrouck, V ;
Collen, D ;
VandenDriessche, T .
HUMAN GENE THERAPY, 2000, 11 (05) :729-738
[10]   Mesenchymal stem cells: Biology and potential clinical uses [J].
Deans, RJ ;
Moseley, AB .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (08) :875-884